Oncolytic Myxoma virus Increases Autophagy in Multiple Myeloma

IF 1.5 4区医学 Q3 HEMATOLOGY

Turkish Journal of Hematology Pub Date : 2024-03-01 Epub Date: 2024-01-23 DOI:10.4274/tjh.galenos.2024.2023.0403

Alpay Yeşilaltay, Dilek Muz, Berna Erdal

{"title":"Oncolytic Myxoma virus Increases Autophagy in Multiple Myeloma","authors":"Alpay Yeşilaltay, Dilek Muz, Berna Erdal","doi":"10.4274/tjh.galenos.2024.2023.0403","DOIUrl":null,"url":null,"abstract":"Objective: Multiple myeloma, which affects plasma cells, is the second most common hematological malignancy. Despite the development of new drugs and treatment protocols, patient survival has not reached the desired level. In this study, we investigated the effects of Myxoma virus (MYXV), an oncolytic virus, on autophagy in myeloma cells.Materials and methods: We analyzed protein expressions of ATG-5, p62, Beclin-1, LC3B, and the apoptosis marker Bcl-2 as autophagy markers in human U-266 and mouse MOPC-315 myeloma cell lines subjected to different doses of MYXV. In addition, autophagic images of myeloma cells were investigated using transmission electron microscopy (TEM).Results: In the first 24 h, which is the early stage of autophagy, ATG-5 and Beclin-1 expression levels were increased in the U-266 and MOPC-315 cell lines in the groups that had received MYXV at a multiplicity of infection of 15. At 48 h, a significant increase was detected in the expression of LC3B, which is a late indicator. Autophagosomes were observed in myeloma cells by TEM.Conclusion: MYXV shows an antimyeloma effect by increasing autophagy in myeloma cells.","PeriodicalId":23362,"journal":{"name":"Turkish Journal of Hematology","volume":" ","pages":"16-25"},"PeriodicalIF":1.5000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10918390/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Turkish Journal of Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4274/tjh.galenos.2024.2023.0403","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: Multiple myeloma, which affects plasma cells, is the second most common hematological malignancy. Despite the development of new drugs and treatment protocols, patient survival has not reached the desired level. In this study, we investigated the effects of Myxoma virus (MYXV), an oncolytic virus, on autophagy in myeloma cells.

Materials and methods: We analyzed protein expressions of ATG-5, p62, Beclin-1, LC3B, and the apoptosis marker Bcl-2 as autophagy markers in human U-266 and mouse MOPC-315 myeloma cell lines subjected to different doses of MYXV. In addition, autophagic images of myeloma cells were investigated using transmission electron microscopy (TEM).

Results: In the first 24 h, which is the early stage of autophagy, ATG-5 and Beclin-1 expression levels were increased in the U-266 and MOPC-315 cell lines in the groups that had received MYXV at a multiplicity of infection of 15. At 48 h, a significant increase was detected in the expression of LC3B, which is a late indicator. Autophagosomes were observed in myeloma cells by TEM.

Conclusion: MYXV shows an antimyeloma effect by increasing autophagy in myeloma cells.

查看原文本刊更多论文

肿瘤溶解性肌瘤病毒可增强多发性骨髓瘤的自噬作用

背景：多发性骨髓瘤（MM）会影响浆细胞，是第二大最常见的血液恶性肿瘤。尽管开发了新的药物和治疗方案，但患者的存活率仍未达到理想水平。在这项研究中，我们研究了溶瘤病毒（MYXV）对骨髓瘤细胞自噬的影响：我们分析了经不同剂量 MYXV 处理的人 U-266 和小鼠 MOPC 315 骨髓瘤细胞系中作为自噬标记物的 ATG-5、p62、Beclin-1、LC3B 和凋亡标记物 Bcl-2 的蛋白表达。此外，还使用透射电子显微镜（TEM）研究了骨髓瘤细胞的自噬图像：结果：在自噬的早期阶段，即最初的 24 小时内，接受 15 倍量 MYXV 感染的 U-266 和 MOPC-315 细胞系中 ATG-5 和 Beclin-1 的表达均有所增加。48 小时后，检测到作为晚期指标的 LC3B 表达明显增加。在 TEM 上观察到骨髓瘤细胞中有自噬体：结论：MYXV 可通过增加骨髓瘤细胞的自噬作用来达到抗骨髓瘤的效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Turkish Journal of Hematology HEMATOLOGY-

CiteScore

2.90

自引率

3.80%

发文量

审稿时长

1 months

期刊介绍： The Turkish Journal of Hematology is published quarterly (March, June, September, and December) by the Turkish Society of Hematology. It is an independent, non-profit peer-reviewed international English-language periodical encompassing subjects relevant to hematology. The Editorial Board of The Turkish Journal of Hematology adheres to the principles of the World Association of Medical Editors (WAME), International Council of Medical Journal Editors (ICMJE), Committee on Publication Ethics (COPE), Consolidated Standards of Reporting Trials (CONSORT) and Strengthening the Reporting of Observational Studies in Epidemiology (STROBE). The aim of The Turkish Journal of Hematology is to publish original hematological research of the highest scientific quality and clinical relevance. Additionally, educational material, reviews on basic developments, editorial short notes, images in hematology, and letters from hematology specialists and clinicians covering their experience and comments on hematology and related medical fields as well as social subjects are published. As of December 2015, The Turkish Journal of Hematology does not accept case reports. Important new findings or data about interesting hematological cases may be submitted as a brief report.